Filing Flows › Comparisons › RVTY vs BIO
Revvity vs Bio-Rad Laboratories: RVTY and BIO compared
Revvity is the larger company: $729M of revenue in its latest quarter (Q3 2026) against $656M for Bio-Rad Laboratories (Q3 2026). Revvity is growing faster (+4% against +0.5% a year earlier). Revvity is more profitable, with an operating margin of 10.6% against -7.6%.
Where the money goes: RVTY and BIO
Revvity (RVTY) · Q3 2026
Revvity, Q3 2026: revenue $729M (+4% year over year), operating margin 10.6%, net earnings $62.3M, operating cash flow $167M. The chart follows the revenue to costs, profit and cash.
Bio-Rad Laboratories (BIO) · Q3 2026
Bio-Rad Laboratories, Q3 2026: revenue $656M (+0.5% year over year), operating margin -7.6%, net earnings $459M, operating cash flow $96.4M. The chart follows the revenue to costs, profit and cash.
| Revvity (RVTY) | Bio-Rad Laboratories (BIO) | |
|---|---|---|
| Latest quarter | Q3 2026 | Q3 2026 |
| Revenue | $729M | $656M |
| Revenue growth, Y/Y | +4% | +0.5% |
| Operating margin | 10.6% | -7.6% |
| Net earnings | $62.3M | $459M |
| Net margin | 8.5% | 69.9% |
| Operating cash flow | $167M | $96.4M |
| Free cash flow | $152M | $65.2M |
| Market value | $17.3B | $10.3B |
| P/E | 72.9× | 10.1× |
| Analysts’ mean target | $171.07 | $335.00 |
Where the revenue comes from
Revvity
- Life Sciences: $380M (52%)
- Diagnostics: $349M (48%)
Bio-Rad Laboratories
- Clinical Diagnostics: $402M (61%)
- Life Science: $255M (39%)
Questions
Which is bigger, Revvity or Bio-Rad Laboratories?
Revvity is the larger company: $729M of revenue in its latest quarter (Q3 2026) against $656M for Bio-Rad Laboratories (Q3 2026).
Is Revvity or Bio-Rad Laboratories growing faster?
Revvity is growing faster (+4% against +0.5% a year earlier).
Which is more profitable, Revvity or Bio-Rad Laboratories?
Revvity is more profitable, with an operating margin of 10.6% against -7.6%.
More: Revvity earnings · how Revvity makes money · Bio-Rad Laboratories earnings · how Bio-Rad Laboratories makes money
From the companies' latest 10-Q, 10-K or earnings release (8-K filed Nov 3, 2026; 10-Q filed Nov 4, 2026). Fiscal quarters can end on different dates. Not investment advice.